Victoria Socha

DocwireNews

Patients with chronic kidney disease (CKD) and 
metabolic acidosis are at increased risk for CKD progression and experience 
significant muscle- and bone-related adverse events. Sankar D. Navaneethan, 
MD, MS, MPH, and colleagues conducted a systematic review and meta-analysis 
to examine the benefits and risks of treatment of metabolic acidosis with oral 
alkali supplementation or a reduction of dietary acid intake in patients with 
CKD. Results of the review were reported in the Clinical Journal of the 
American Society of Nephrology [2019;14(7):1011-1020].Relevant trials involving patients with stage 
3-5 CKD and metabolic acidosis (&lt;22 mEq/L) or low-normal serum bicarbonate 
(22-24 mEq/L) were identified via searches in MEDLINE, Embase, and Cochrane 
CENTRAL. Data were pooled in a meta-analysis, and random effects models were 
used to express results as weighted mean difference for continuous outcomes and 
relative risk for categorical outcomes with 95% confidence intervals (CI). 
Cochrane risk of bias and criteria from the Grading of Recommendations 
Assessment, Development, and Evaluation were used to assess study quality and 
strength of evidence.The meta-analysis included 14 trials 
representing 1394 participants. In the 14 studies, serum bicarbonate levels 
were increased with treatment of metabolic acidosis with oral alkali 
supplementation or a reduction in dietary acid intake (1378 patients; mean 
difference, 3.33 mEq/L; 95% CI, 2.37-4.29). In 13 studies, treatment resulted 
in a slower decline in estimated glomerular filtration rate (1329 patients; 
mean difference, &ndash;3.28 mL/min/1.73 m2; 95% CI, &ndash;4.42 to &ndash;2.14; 
moderate certainty), as well as a reduction in urinary albumin excretion 
(very-low certainty) and a reduction in the risk of progression to end-stage 
renal disease (ESRD; relative risk, 0.32; 95% CI, 0.18-0.56; low certainty). 
There was an association between oral alkali supplementation and worsening 
hypertension or the need for increased antihypertensive therapy (very-low 
certainty).In summary, the researchers said, &ldquo;Current 
clinical trial evidence suggests that oral alkali supplementation or a 
reduction of dietary acid load improved serum bicarbonate levels and may slow 
the progression of kidney disease on the basis of very-low- to 
moderate-certainty clinical evidence. Further larger, long-term studies of 
better quality are warranted to establish the benefits (such as delaying initiation 
of kidney replacement therapy or slowing progression to ESRD) and risks of 
treatment with oral alkali and/or a reduction in dietary acid load in patients 
with CKD.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Treating Metabolic Acidosis in Patients with CKD: A Systematic Review and Meta-Analysis

Chronic Kidney Disease

Patients with chronic kidney disease (CKD) and metabolic acidosis are at increased risk for CKD progression and experience significant muscle- and bone-related adverse events. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe